PHARMINNOVA P.C. is an experienced, consulting group focused on the global pharmaceutical industry, covering services for an extensive portfolio of medicinal products.
We are always up to date with current legislation, regulatory requirements, industry initiatives and interpretations of the regulations and scientific guidelines. PHARMINNOVA scientific staff and collaborating experts will ensure that you have access to the right level of skills and experience, along with the flexibility that your project requires. Having previous work experience inside regulatory agencies at the national and international level, as well as within pharma industry, bring a unique level of insight and expertise to our work. Our ability to respond quickly and flexibly to ever-changing client needs in a complex regulatory environment combined with a consistent and dedicated commitment to quality services are important elements of advantage.
PHARMINNOVA experts, having vast experience in a variety of areas, such as strategic and scientific advice, regulatory affairs, business and product development, dossier compilation etc, develop creative approaches to assist you in bringing your products to any market.
The aim of PHARMINNOVA is to provide our customers with a reliable, flexible and effective strategic regulatory and scientific affairs service, covering all stages of pharmaceutical development and authorisation process in a timely and cost-effective manner. Our mission is to assist pharmaceutical companies in rationalizing drug development and we use innovative approaches and services, in order to translate the scientific knowledge into tangible benefits for patient care.
Guiding you all the way up
Founder/Managing Director and Senior Consultant
Chrysa Daousani is the Founder/Managing Director and Senior Consultant of
PHARMINNOVA P.C. Chrysa is an Expert in Clinical/Pharmacokinetic and
Non-clinical assessment and regulatory science, being a Consultant in the
Pharma Industry, since early 2014.
Before that, she worked as a Clinical/Pharmacokinetic and Non-Clinical
Assessor at the Greek National Organisation for Medicines-EOF (2003-2014),
where she coordinated and provided assessment for Centralised,
Decentralised, Mutual Recognition and National procedures for medicinal
products for human use, as well as for scientific and regulatory advice.
During her engagement in the Greek Agency, she represented Greece as
EOF delegate in the Committee for Medicinal Products for Human Use-CHMP
at the European Medicines Agency (EMA) (2012-2014) and also in the Co-
ordination Group for Mutual Recognition and Decentralised procedure-CMD- h
She holds a B.Sc. in Pharmacy from School of Pharmacy, National and
Kapodistrian University of Athens, Greece, where she has also gained her
M.Sc. from Department of Pharmaceutical Chemistry.
Currently she is also a researcher (Ph.D. candidate) in the Department of
Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian
University of Athens, Greece. Her scientific interests include areas such as
biopharmaceutics, pharmacokinetics and bioequivalence,
bioanalysis/bioanalytical methods, drug ADME-T processes, modeling and
simulation in drug development.
She has also received high-level scientific training from Academic and other
Organisations, as well as from the EMA on Clinical and Non-
Clinical/Toxicological Assessment of medicinal products.
Co-Owner and Business Development Director
Evangelos (Vangelis) A. Karras has joined Pharminnova P.C. in 2017. He is
Co-Owner and the Business Development Director of the company.
He has experience with a demonstrated history of working in various
fields in the pharmaceutical industry for 20 years. He began his career in 1998
as a Regulatory Affairs and R&D Officer in a Greek Pharmaceutical Company,
specialized in the development of generic pharmaceutical products. In 2004
he joined a Greek Pharmaceutical Industry as Registration Manager and QS
Compliance Manager. In 2008 he joined a Greek Pharmaceutical Trading
Company as Raw Materials Sales Director and in 2013 he was appointed as
Qualified Person by the Greek National Organization for Medicines.
Vangelis holds a Ph.D. in Biochemistry and Immunology, from School
of Medicine of the National and Kapodistrian University of Athens, Greece, an
M.Sc. in Clinical Biochemistry from the University of Newcastle Upon Tyne,
United Kingdom and a B.Sc. in Biochemistry from the University of Liverpool,
He had a successful research collaboration with The Hellenic Pasteur
Institute, Department Of Biochemistry, Athens, Greece, The Memorial
University of Newfoundland, Faculty of Medicine, Divisions of Endocrinology
and Biomedical Sciences, St. John’s, Canada and The University of Texas,
Medical Branch, Department of Microbiology & Immunology, Galveston
Island, United States of America.
Apart from the scientific training, he had also received specialized
education. He participated in the Lloyd’s Register Quality Assurance (LRQA)
Organization, in Internal QMS Auditor Course, in ISO Training Course and in
Naftermporiki SA, Academy of Sales, Management and Business
PHARMINNOVA is in close collaboration with experienced and reliable partners worldwide (including CROs, CDMOs, Pharma Companies, as well as with Academic Institutions), utilized on a per-project basis.
Our clients include many pharmaceutical companies around the world.